Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108953 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT00108953 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 96 participants.
The verdict
NCT00108953, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- DRUG Doxorubicin/Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108953
The ClinicalTrials.gov registry entry for NCT00108953 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin is the first listed.
NCT00108953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108953 about?
NCT00108953 is a clinical study titled "A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma". The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
What is the current status of trial NCT00108953?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2005-04. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00108953?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin (DRUG), Doxorubicin/Placebo (DRUG).
Who is sponsoring clinical trial NCT00108953?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.